Page last updated: 2024-10-24
celecoxib and Nycturia
celecoxib has been researched along with Nycturia in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 9.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 5.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Falahatkar, S | 1 |
| Mokhtari, G | 1 |
| Pourreza, F | 1 |
| Asgari, SA | 1 |
| Kamran, AN | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in the International Prostate Symptom Score (IPSS) Questionnaires
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 12.0 | 7.70 | -4.31 |
,| Study Group | 13.1 | 6.45 | -6.63 |
Change From Baseline in the IPSS Subscore (IPSS Storage) Questionnaires
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 6.06 | 4.01 | -2.05 |
,| Study Group | 5.59 | 3.09 | -2.5 |
Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 5.54 | 3.45 | -2.09 |
,| Study Group | 7.55 | 3.84 | -3.71 |
Change From Baseline in the Maximum Flow Rate (Qmax)
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 10.0 | 11.9 | 1.9 |
,| Study Group | 12.2 | 12.2 | -0.09 |
Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 15.2 | 13.5 | -1.70 |
,| Study Group | 10.8 | 9.42 | -1.43 |
Change From Baseline in the Void Volume (VV)
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) |
|---|
| Baseline | 3 months | Change |
|---|
| Control Group | 175 | 231 | 55.7 |
,| Study Group | 259 | 227 | -32.3 |
Trials
1 trial available for celecoxib and Nycturia